A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV.

"Conflicts of interest H.Z., J.T.H., L.L., M.D., J.S., D.X., P.A., R.P., S.G., and D.D.M. declare employment and restricted stocks from Gilead Sciences. A.A. declares research grants from Gilead Sciences, GSK, and MSD."

"We thank all participants and investigators involved in the study. We also thank Hal Martin, MD, MPH, for contributions to the protocol design, execution, analysis, and reporting; Hailin Huang, PhD, for contributions as the lead study statistician; Polina German, PharmD, for contributions to the study design and conception; as well as Anuja Raut, MS, Associate Director, Clinical Pharmacology, and Paige Daniel, PhD, Associate Scientist, Clinical Pharmacology (Certara USA, Inc.), for performing final pharmacokinetic noncompartmental analyses. Medical writing support was provided by Olivia Morris, PhD, at Aspire Scientific Limited (Bollington, UK). Funding for medical writing support for this article was provided by Gilead Sciences (Foster City, CA, USA). Author contributions – Conceptualization: H.Z. Data curation: J.S., M.D. Formal analysis: H.Z., D.X., J.S., D.D.M. Funding acquisition: none. Investigation: H.Z., J.T.H., L.L., J.S., D.X., A.A., P.A., R.P., S.G., D.D.M. Methodology: H.Z., D.X., M.D., J.S. Project administration: none. Resources: J.T.H., R.P., S.G., D.D.M. Software: H.Z., J.S. Supervision: J.T.H., R.P., S.G., D.D.M. Validation: H.Z., D.X., M.D., J.S. Visualization: H.Z., J.S. Writing – original draft: H.Z., D.D.M. Writing – review and editing: H.Z., J.T.H., L.L., M.D., J.S., D.X., A.A., P.A., S.G., D.D.M. Funding: this study was funded by Gilead Sciences (Foster City, California, USA). The study sponsor, Gilead Sciences (Foster City, California, USA), played a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript."